P/B
—
UroGen Pharma
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
$1.8B
Market Cap • 10/9/2026
2004
(22 years)
Founded
2017
(9 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
9,5
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
—
EPS
—
Market Cap
Market Cap
1,8B
EV
1,9B
EV/Revenue
10
EV/EBITDA
-29,5
EV/EBIT
-28,3
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-2,4%
Total Yield
-2,4%
Payout
0%
Retained Earnings
-997,6M
Profitability
Gross Margin
90,8%
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
32,5%
Capex/Revenue
0,1%
Capex/D&A
8,3%
Capex/OCF
-0,1%
SBC/OCF
—
% PPE
3,3%
% Goodwill
0%
ROE
86,5%
ROIC
—
Growth
CAGR Revenue 5Y
42,7%
CAGR Op. Income 5Y
-8,7%
CAGR Net Income 5Y
-2,6%
CAGR EPS 5Y
-17%
CAGR OCF 5Y
11,4%
Leverage
N.D./EBITDA
—
Debt/Equity
0%
Current Ratio
3,8
Quick Ratio
3,2
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!